Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.
Aspen secures licensing agreement to enter GLP-1 market
Original Article by Nompilo Goba | Business Day | 30 October 2024
Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.
More Posts
Compounded semaglutide appeal dismissed
A court has upheld restrictions on compounded semaglutide at iDexis while regulatory investigations continue.
Read more...
WHO’s Africa Chief Urges Action, Not Talk, on Primary Healthcare
WHO Africa director Mohamed Janabi urged governments to finance primary healthcare and pursue health sovereignty.
Read more...
Unpaid specialist training strains SA doctors
Unpaid specialist training is growing in South Africa as scarce funded posts leave doctors working without salaries.
Read more...